Biogen, Eisai to shift some Alzheimer's drug production to US / Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short / Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction / Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction / Biogen is buying up an immune drug developer for $1.8 billion / Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup / Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up / Biogen dumps dubious Alzheimer's drug after profit-killing FDA scandal / Biogen Plans to Shut Down Its Controversial Alzheimer's Drug Aduhelm / Biogen to shut down its controversial Alzheimer's drug Aduhelm